Svensson M et al. |
Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. |
2002 |
Antimicrob. Agents Chemother. |
pmid:12069981
|
Comley JC and Sterling AM |
Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. |
1995 |
Antimicrob. Agents Chemother. |
pmid:7785975
|
Struillou L et al. |
Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. |
1995 |
Antimicrob. Agents Chemother. |
pmid:7785988
|
Goswami S et al. |
Anti-Helicobacter pylori potential of artemisinin and its derivatives. |
2012 |
Antimicrob. Agents Chemother. |
pmid:22687518
|
Taylor DE et al. |
Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9420030
|
Nash KA and Inderlied CB |
Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. |
1995 |
Antimicrob. Agents Chemother. |
pmid:8592991
|
Cho SH et al. |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
2007 |
Antimicrob. Agents Chemother. |
pmid:17210775
|
Ji B et al. |
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. |
2007 |
Antimicrob. Agents Chemother. |
pmid:17664316
|
Vaara M |
Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8383945
|
Fujii K et al. |
In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. |
1994 |
Antimicrob. Agents Chemother. |
pmid:8067748
|
Bakker-Woudenberg IA et al. |
Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. |
2005 |
Antimicrob. Agents Chemother. |
pmid:15917538
|
Traunmüller F et al. |
Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. |
2007 |
Antimicrob. Agents Chemother. |
pmid:17606673
|
Romand S et al. |
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8285620
|
Yasuda H et al. |
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8239580
|
Alder J et al. |
Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8328782
|
Mor N and Heifets L |
Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8328792
|
Rastogi N et al. |
Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1667250
|
Lazard T et al. |
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8215285
|
Koh WJ et al. |
Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. |
2015 |
Antimicrob. Agents Chemother. |
pmid:25987622
|
Riska PF et al. |
Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. |
2004 |
Antimicrob. Agents Chemother. |
pmid:15328134
|
Hultén K et al. |
New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. |
1996 |
Antimicrob. Agents Chemother. |
pmid:9124830
|
Inderlied CB et al. |
Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. |
1994 |
Antimicrob. Agents Chemother. |
pmid:7986017
|
Bermudez LE et al. |
Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. |
1994 |
Antimicrob. Agents Chemother. |
pmid:7986018
|
Khan AA et al. |
Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9145840
|
Collins L and Franzblau SG |
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9145860
|
Lounis N et al. |
Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9145892
|
Cavalieri SJ et al. |
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. |
1995 |
Antimicrob. Agents Chemother. |
pmid:7492101
|
Bosnar M et al. |
Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. |
2005 |
Antimicrob. Agents Chemother. |
pmid:15917536
|
Hardy DJ et al. |
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. |
1990 |
Antimicrob. Agents Chemother. |
pmid:2143642
|
Subramanian S et al. |
Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. |
2008 |
Antimicrob. Agents Chemother. |
pmid:18070962
|
Moon JE et al. |
Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. |
2006 |
Antimicrob. Agents Chemother. |
pmid:16723556
|
Burton AJ et al. |
Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. |
2015 |
Antimicrob. Agents Chemother. |
pmid:25824218
|
Leuthner KD et al. |
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. |
2006 |
Antimicrob. Agents Chemother. |
pmid:16436754
|
Kohyama T et al. |
Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. |
1999 |
Antimicrob. Agents Chemother. |
pmid:10103198
|
GarcÃa-Arata MI et al. |
Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. |
1999 |
Antimicrob. Agents Chemother. |
pmid:9925537
|
Hoffner SE et al. |
Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8392308
|
Walzer PD et al. |
Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9021174
|
Banerjee DK et al. |
Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9021187
|
Schuster S et al. |
Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. |
2016 |
Antimicrob. Agents Chemother. |
pmid:27161641
|
Cirioni O et al. |
Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. |
2008 |
Antimicrob. Agents Chemother. |
pmid:18779356
|
Abduljalil K et al. |
Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. |
2009 |
Antimicrob. Agents Chemother. |
pmid:19414584
|
Phillips RO et al. |
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. |
2014 |
Antimicrob. Agents Chemother. |
pmid:24323473
|
Amsden GW et al. |
Oral cimetidine prolongs clarithromycin absorption. |
1998 |
Antimicrob. Agents Chemother. |
pmid:9660986
|
Liou JM et al. |
Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. |
2011 |
Antimicrob. Agents Chemother. |
pmid:21189342
|
Matic V et al. |
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. |
2004 |
Antimicrob. Agents Chemother. |
pmid:15504828
|
Kosowska K et al. |
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. |
2004 |
Antimicrob. Agents Chemother. |
pmid:15504829
|
Bae S et al. |
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. |
2010 |
Antimicrob. Agents Chemother. |
pmid:19884366
|
Spyridaki A et al. |
Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. |
2012 |
Antimicrob. Agents Chemother. |
pmid:22564837
|
Ednie LM et al. |
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). |
1997 |
Antimicrob. Agents Chemother. |
pmid:9303406
|
Stone GG et al. |
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9056021
|
Tessier PR et al. |
Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. |
2002 |
Antimicrob. Agents Chemother. |
pmid:11959578
|
Ichiyama T et al. |
Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. |
2001 |
Antimicrob. Agents Chemother. |
pmid:11120942
|
Bohnert JA et al. |
Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. |
2016 |
Antimicrob. Agents Chemother. |
pmid:26824939
|
Ji B et al. |
Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1828136
|
Ramón-GarcÃa S et al. |
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. |
2011 |
Antimicrob. Agents Chemother. |
pmid:21576426
|
Cohen Y et al. |
Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. |
1992 |
Antimicrob. Agents Chemother. |
pmid:1332586
|
Miltner EC and Bermudez LE |
Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. |
2000 |
Antimicrob. Agents Chemother. |
pmid:10858369
|
Kawai Y et al. |
Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. |
2013 |
Antimicrob. Agents Chemother. |
pmid:23459497
|
Nakamura S et al. |
Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. |
2010 |
Antimicrob. Agents Chemother. |
pmid:19949056
|
Mukherjee D et al. |
Vancomycin and Clarithromycin Show Synergy against . |
2017 |
Antimicrob. Agents Chemother. |
pmid:28923867
|
Jorgensen JH et al. |
Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1834012
|
Tsay FW et al. |
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. |
2017 |
Antimicrob. Agents Chemother. |
pmid:28807915
|
Greendyke R and Byrd TF |
Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
2008 |
Antimicrob. Agents Chemother. |
pmid:18378709
|
Choi GE et al. |
Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. |
2012 |
Antimicrob. Agents Chemother. |
pmid:22564831
|
Jesus FP et al. |
In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. |
2015 |
Antimicrob. Agents Chemother. |
pmid:26459895
|
Bermudez LE et al. |
Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. |
2000 |
Antimicrob. Agents Chemother. |
pmid:10991834
|
Hsu PI et al. |
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. |
2014 |
Antimicrob. Agents Chemother. |
pmid:25070099
|
Wang G et al. |
Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. |
2001 |
Antimicrob. Agents Chemother. |
pmid:11181351
|
van Doorn LJ et al. |
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. |
2001 |
Antimicrob. Agents Chemother. |
pmid:11302817
|
Rastogi N et al. |
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. |
2000 |
Antimicrob. Agents Chemother. |
pmid:10991870
|
Piccolomini R et al. |
In vitro activity of clarithromycin against intracellular Helicobacter pylori. |
2001 |
Antimicrob. Agents Chemother. |
pmid:11302831
|
Secka O et al. |
Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. |
2013 |
Antimicrob. Agents Chemother. |
pmid:23263004
|
Fernandes PB et al. |
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. |
1986 |
Antimicrob. Agents Chemother. |
pmid:2949695
|
Falzari K et al. |
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. |
2005 |
Antimicrob. Agents Chemother. |
pmid:15793125
|
Segreti J et al. |
In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952061
|
Alhajlan M et al. |
Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. |
2013 |
Antimicrob. Agents Chemother. |
pmid:23545534
|
Benson CA et al. |
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952063
|
Gelber RH et al. |
Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1648889
|
Brophy DF et al. |
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. |
2000 |
Antimicrob. Agents Chemother. |
pmid:10722500
|
Matsuzaki J et al. |
Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. |
2012 |
Antimicrob. Agents Chemother. |
pmid:22203601
|
Yamaguchi H et al. |
Chlamydia pneumoniae resists antibiotics in lymphocytes. |
2003 |
Antimicrob. Agents Chemother. |
pmid:12760877
|
Mor N and Esfandiari A |
Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9303411
|
Goldstein EJ and Citron DM |
Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. |
1993 |
Antimicrob. Agents Chemother. |
pmid:8390810
|
Giamarellos-Bourboulis EJ et al. |
Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. |
2004 |
Antimicrob. Agents Chemother. |
pmid:14693524
|
Hultén K et al. |
Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9371366
|
Carter G et al. |
A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. |
2004 |
Antimicrob. Agents Chemother. |
pmid:15561879
|
Yamazaki T et al. |
Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
2007 |
Antimicrob. Agents Chemother. |
pmid:17387152
|
Polis MA et al. |
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. |
1997 |
Antimicrob. Agents Chemother. |
pmid:9257746
|
Walker KJ et al. |
Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. |
1994 |
Antimicrob. Agents Chemother. |
pmid:7811010
|
Bogdanovich T et al. |
Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. |
2006 |
Antimicrob. Agents Chemother. |
pmid:16495248
|
Berti AD et al. |
Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. |
2012 |
Antimicrob. Agents Chemother. |
pmid:22802248
|
Zhanel GG and Karlowsky JA |
In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. |
2009 |
Antimicrob. Agents Chemother. |
pmid:19139284
|
Welsh L et al. |
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. |
1996 |
Antimicrob. Agents Chemother. |
pmid:8787907
|
Liu KY et al. |
Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. |
2014 |
Antimicrob. Agents Chemother. |
pmid:24687504
|
Chen D et al. |
Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. |
2017 |
Antimicrob. Agents Chemother. |
pmid:28167563
|
Nagaoka K et al. |
Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. |
2013 |
Antimicrob. Agents Chemother. |
pmid:23380724
|
Renvoisé A et al. |
Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. |
2015 |
Antimicrob. Agents Chemother. |
pmid:26324275
|
Obregón-Henao A et al. |
Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. |
2015 |
Antimicrob. Agents Chemother. |
pmid:26303795
|
Nash KA |
Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). |
2003 |
Antimicrob. Agents Chemother. |
pmid:14506008
|
Best LM et al. |
Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. |
2003 |
Antimicrob. Agents Chemother. |
pmid:14506021
|